

# Alan P Venook

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2274462/publications.pdf>

Version: 2024-02-01

63  
papers

4,587  
citations

201674

27  
h-index

133252

59  
g-index

65  
all docs

65  
docs citations

65  
times ranked

7489  
citing authors

#	ARTICLE	IF	CITATIONS
1	NCCN Guidelines Insights: Colon Cancer, Version 2.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 359-369.	4.9	675
2	Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 2392.	7.4	670
3	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in <i>BRAF</i> V600E Mutant Colorectal Cancer. Journal of Clinical Oncology, 2015, 33, 4023-4031.	1.6	430
4	Impact of primary (1 <sup>st</sup> ) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).. Journal of Clinical Oncology, 2016, 34, 3504-3504.	1.6	249
5	Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. Journal of Clinical Oncology, 2019, 37, 1217-1227.	1.6	234
6	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal Anal Task Forces whitepaper. Nature Reviews Clinical Oncology, 2020, 17, 757-770.	27.6	218
7	Phase I and Pharmacokinetic Trial of Gemcitabine in Patients With Hepatic or Renal Dysfunction: Cancer and Leukemia Group B 9565. Journal of Clinical Oncology, 2000, 18, 2780-2787.	1.6	177
8	Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). Journal of Clinical Oncology, 2019, 37, 1876-1885.	1.6	169
9	Dietary Glycemic Load and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings From CALGB 89803. Journal of the National Cancer Institute, 2012, 104, 1702-1711.	6.3	163
10	Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis. JAMA Oncology, 2018, 4, 783.	7.1	147
11	TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. Radiology, 2016, 279, 630-640.	7.3	109
12	Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncology, 2017, 3, 1043.	7.1	98
13	Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance). Clinical Cancer Research, 2013, 19, 6957-6966.	7.0	95
14	Initiation of warfarin therapy. Journal of General Internal Medicine, 1987, 2, 141-148.	2.6	94
15	Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer, 2005, 103, 2435-2446.	4.1	72
16	Liver transplantation for hepatocellular carcinoma: Results with preoperative chemoembolization. Liver Transplantation, 1995, 1, 242-248.	1.8	70
17	Self-monitoring and reminder text messages to increase physical activity in colorectal cancer survivors (Smart Pace): a pilot randomized controlled trial. BMC Cancer, 2019, 19, 218.	2.6	66
18	Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance). PLoS ONE, 2014, 9, e99816.	2.5	65

#	ARTICLE	IF	CITATIONS
19	Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). <i>Journal of Clinical Oncology</i> , 2016, 34, 3047-3053.	1.6	51
20	Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of Clinical Oncology</i> , 2019, 37, 2620-2631.	1.6	51
21	Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). <i>Clinical Cancer Research</i> , 2019, 25, 7497-7505.	7.0	44
22	Subgroups of chemotherapy patients with distinct morning and evening fatigue trajectories. <i>Supportive Care in Cancer</i> , 2016, 24, 1473-1485.	2.2	42
23	Impact of Physical Activity After Cancer Diagnosis on Survival in Patients With Recurrent Colon Cancer: Findings From CALGB 89803/Alliance. <i>Clinical Colorectal Cancer</i> , 2013, 12, 233-238.	2.3	31
24	A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2702-2709.	4.1	30
25	Being Present: A single-arm feasibility study of audio-based mindfulness meditation for colorectal cancer patients and caregivers. <i>PLoS ONE</i> , 2018, 13, e0199423.	2.5	29
26	25-Hydroxyvitamin D Levels and Survival in Advanced Pancreatic Cancer: Findings From CALGB 80303 (Alliance). <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	28
27	Gene Expression Profiling of Evening Fatigue in Women Undergoing Chemotherapy for Breast Cancer. <i>Biological Research for Nursing</i> , 2016, 18, 370-385.	1.9	28
28	Clinical Validation of a Machine-learningâ€‘derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1174-1183.	7.0	28
29	Cancer and Leukemia Group B/Southwest Oncology Group Trial 80405: A Phase III Trial of Chemotherapy and Biologics for Patients with Untreated Advanced Colorectal Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2005, 5, 292-294.	2.3	27
30	Generalizability of Trial Results to Elderly Medicare Patients With Advanced Solid Tumors (Alliance) Tj ETQq0 0 0 rgBT./Overlock 10 Tf 50	6.3	27
31	Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 860-874.	1.4	27
32	Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 1713.	7.1	24
33	Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of the National Cancer Institute</i> , 2022, 114, 427-435.	6.3	24
34	Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz078.	2.9	22
35	Bloodâ€‘based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from <sc>CALGB</sc> 80203 (Alliance). <i>Cancer Medicine</i> , 2016, 5, 2249-2260.	2.8	19
36	Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 109-126.	1.4	19

#	ARTICLE	IF	CITATIONS
37	Comparison of Dietary and Lifestyle Habits Among Stage III and Metastatic Colorectal Cancer Patients: Findings from CALGB 89803 and CALGB 80405. <i>Clinical Colorectal Cancer</i> , 2013, 12, 95-102.	2.3	17
38	Differential Radiographic Appearance of BRAF V600E Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1536-1543.	4.9	17
39	BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1386-1395.	6.3	17
40	RasGRP1 is a potential biomarker for stratifying anti-EGFR therapy response in colorectal cancer. <i>JCI Insight</i> , 2019, 4, .	5.0	17
41	Feasibility and Acceptability of a Web-Based Dietary Intervention with Text Messages for Colorectal Cancer: A Randomized Pilot Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 752-760.	2.5	15
42	Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). <i>Clinical Cancer Research</i> , 2018, 24, 4734-4744.	7.0	14
43	Clinicopathologic Characteristics and Impact of Oophorectomy for Ovarian Metastases from Colorectal Cancer. <i>Oncologist</i> , 2020, 25, 564-571.	3.7	14
44	Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). <i>Clinical Cancer Research</i> , 2021, 27, 267-275.	7.0	13
45	Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1705-1713.	6.3	12
46	Therapeutic approaches to metastasis confined to the liver. <i>Current Oncology Reports</i> , 2001, 3, 109-115.	4.0	11
47	Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance). <i>Clinical Cancer Research</i> , 2022, 28, 2779-2788.	7.0	11
48	Colorectal Cancer: All Hands on Deck. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , 83-89.	3.8	9
49	On the Verge: Immunotherapy for Colorectal Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 970-978.	4.9	9
50	Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa024.	2.9	8
51	Quality of life of colorectal cancer survivors participating in a pilot randomized controlled trial of physical activity trackers and daily text messages. <i>Supportive Care in Cancer</i> , 2022, 30, 4557-4564.	2.2	7
52	A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma. <i>Anticancer Research</i> , 2014, 34, 7357-60.	1.1	7
53	Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab. <i>Clinical Cancer Research</i> , 2022, 28, 1690-1700.	7.0	7
54	IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa074.	2.9	6

#	ARTICLE	IF	CITATIONS
55	Feasibility and Acceptability of a Physical Activity Tracker and Text Messages to Promote Physical Activity During Chemotherapy for Colorectal Cancer: Pilot Randomized Controlled Trial (Smart Pace) Tj ETQq1 1 0.284314 rgBT /Over	2.8	6
56	Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer—70 years. <i>European Journal of Cancer</i> , 2022, 163, 1-15.	2.2	4
57	Colorectal metastases confined to the liver: a unique opportunity?. <i>Seminars in Oncology</i> , 2003, 30, 34-39.	2.9	4
58	Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance). <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab034.	3.2	3
59	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110205.	2.3	1
60	Heated Intraperitoneal Chemotherapy for Colorectal Carcinomatosis: Emerging Evidence. <i>Clinical Colorectal Cancer</i> , 2020, 19, 1-4.	1.6	0
61	Reply to L. Casadaban et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1373-1374.	3.4	0
62	Of Microbes and Microsatellites. <i>Cancer Immunology Research</i> , 2018, 6, 1290-1291.	4.9	0
63	Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2004, 2 Suppl 2, S74-84.		